Stocks and InvestingStocks and Investing
Thu, March 31, 2022
Wed, March 30, 2022
Tue, March 29, 2022
Mon, March 28, 2022
Sun, March 27, 2022
Fri, March 25, 2022
Thu, March 24, 2022

Liisa Bayko Maintained (VRTX) at Buy and Held Target at $265 on, Mar 24th, 2022


Published on 2024-10-27 20:11:20 - WOPRAI, Liisa Bayko
  Print publication without navigation


Liisa Bayko of Evercore ISI Group, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy and Held Target at $265 on, Mar 24th, 2022.

Liisa has made no other calls on VRTX in the last 4 months.



There are 8 other peers that have a rating on VRTX. Out of the 8 peers that are also analyzing VRTX, 2 agree with Liisa's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $269 on, Wednesday, February 16th, 2022
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $222 on, Thursday, January 27th, 2022


These are the ratings of the 6 analyists that currently disagree with Liisa


  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Wednesday, March 23rd, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022
  • Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $274 on, Thursday, January 20th, 2022
  • Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $270 on, Thursday, December 9th, 2021
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $341 on, Wednesday, December 1st, 2021
  • Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $286 on, Wednesday, December 1st, 2021